HALO vs. META
HALO (Halozyme Therapeutics, Inc.) and META (Meta Platforms, Inc.) are both stocks. HALO operates in Biotechnology (Healthcare), while META operates in Internet Content & Information (Communication Services). Over the past 10 years, HALO returned 22.84%/yr vs 17.39%/yr for META. At a 0.27 correlation, their price movements are largely independent.
Performance
HALO vs. META - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, HALO achieves a 3.27% return, which is significantly higher than META's -14.03% return. Over the past 10 years, HALO has outperformed META with an annualized return of 22.84%, while META has yielded a comparatively lower 17.39% annualized return.
HALO
- 1D
- -1.74%
- 1M
- 0.42%
- YTD
- 3.27%
- 6M
- 11.72%
- 1Y
- 28.75%
- 3Y*
- 27.10%
- 5Y*
- 10.19%
- 10Y*
- 22.84%
META
- 1D
- -0.26%
- 1M
- -8.32%
- YTD
- -14.03%
- 6M
- -11.84%
- 1Y
- -16.71%
- 3Y*
- 28.18%
- 5Y*
- 11.52%
- 10Y*
- 17.39%
HALO vs. META - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
HALO Halozyme Therapeutics, Inc. | 3.27% | 40.77% | 29.36% | -35.04% | 41.51% | -5.85% | 140.89% | 21.19% | -27.79% | 105.06% |
META Meta Platforms, Inc. | -14.03% | 13.09% | 66.05% | 194.13% | -64.22% | 23.13% | 33.09% | 56.57% | -25.71% | 53.38% |
Correlation
The correlation between HALO and META is 0.01, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.01 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.07 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.22 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.26 |
Correlation (All Time) Calculated using the full available price history since May 18, 2012 | 0.27 |
Over the past year, the correlation between HALO and META has dropped to 0.01 - well below their long-term average of 0.27, suggesting their price drivers have been diverging.
Fundamentals
HALO:
$8.54B
META:
$1.45T
HALO:
$2.87
META:
$27.47
HALO:
24.26
META:
20.64
HALO:
2.74
META:
0.85
HALO:
5.61
META:
6.78
HALO:
38.88
META:
5.97
HALO:
$1.51B
META:
$214.96B
HALO:
$1.23B
META:
$176.14B
HALO:
$980.05M
META:
$106.31B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
HALO vs. META — Risk / Return Rank
HALO
META
HALO vs. META - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Halozyme Therapeutics, Inc. (HALO) and Meta Platforms, Inc. (META). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| HALO | META | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.42 | ||
| Sortino ratioReturn per unit of downside risk | +1.95 | ||
| Omega ratioGain probability vs. loss probability | 1.17 | 0.93 | +0.24 |
| Calmar ratioReturn relative to maximum drawdown | 1.14 | -0.54 | +1.68 |
| Martin ratioReturn relative to average drawdown | 2.16 | -1.12 | +3.28 |
Loading charts...
Drawdowns
HALO vs. META - Drawdown Comparison
The maximum HALO drawdown since its inception was -74.26%, roughly equal to the maximum META drawdown of -76.74%. Use the drawdown chart below to compare losses from any high point for HALO and META.
Loading charts...
Drawdown Indicators
| HALO | META | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -74.26% | -76.74% | +2.48% |
Max Drawdown (1Y)Largest decline over 1 year | -24.13% | -33.30% | +9.17% |
Max Drawdown (3Y)Largest decline over 3 years | -33.92% | -34.15% | +0.23% |
Max Drawdown (5Y)Largest decline over 5 years | -49.06% | -76.74% | +27.68% |
Max Drawdown (10Y)Largest decline over 10 years | -49.06% | -76.74% | +27.68% |
Current DrawdownCurrent decline from peak | -14.44% | -28.06% | +13.62% |
Average DrawdownAverage peak-to-trough decline | -31.88% | -15.83% | -16.05% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.73% | 16.06% | -3.33% |
Volatility
HALO vs. META - Volatility Comparison
The current volatility for Halozyme Therapeutics, Inc. (HALO) is 8.94%, while Meta Platforms, Inc. (META) has a volatility of 10.17%. This indicates that HALO experiences smaller price fluctuations and is considered to be less risky than META based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| HALO | META | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.94% | 10.17% | -1.23% |
Volatility (6M)Calculated over the trailing 6-month period | 24.02% | 26.91% | -2.89% |
Volatility (1Y)Calculated over the trailing 1-year period | 30.20% | 35.52% | -5.32% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 39.42% | 44.04% | -4.62% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 42.88% | 38.67% | +4.21% |
Dividends
HALO vs. META - Dividend Comparison
HALO has not paid dividends to shareholders, while META's dividend yield for the trailing twelve months is around 0.37%.
| Position | TTM | 2025 | 2024 |
|---|---|---|---|
HALO Halozyme Therapeutics, Inc. | 0.00% | 0.00% | 0.00% |
META Meta Platforms, Inc. | 0.37% | 0.32% | 0.34% |
Financials
HALO vs. META - Financials Comparison
This section allows you to compare key financial metrics between Halozyme Therapeutics, Inc. and Meta Platforms, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
HALO vs. META - Profitability Comparison
HALO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a gross profit of 297.47M and revenue of 376.71M. Therefore, the gross margin over that period was 79.0%.
META - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Meta Platforms, Inc. reported a gross profit of 46.09B and revenue of 56.31B. Therefore, the gross margin over that period was 81.9%.
HALO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported an operating income of 184.52M and revenue of 376.71M, resulting in an operating margin of 49.0%.
META - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Meta Platforms, Inc. reported an operating income of 22.87B and revenue of 56.31B, resulting in an operating margin of 40.6%.
HALO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a net income of 150.05M and revenue of 376.71M, resulting in a net margin of 39.8%.
META - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Meta Platforms, Inc. reported a net income of 26.77B and revenue of 56.31B, resulting in a net margin of 47.5%.
Frequently Asked Questions
HALO and META have a correlation of 0.01, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
META has higher volatility (10.17%) compared to HALO (8.94%). In terms of maximum drawdown, HALO dropped -74.26% vs META's -76.74%.
HALO currently has the higher Sharpe Ratio (0.91 vs -0.51), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for HALO and META
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer